


(12) UK Patent Application (19) GB (11) 2 053 220 A

- (21) Application No 8021524
(22) Date of filing 1 Jul 1980
(30) Priority data
(31) 2927004
(32) 4 Jul 1979
(33) Fed. Rep of Germany (DE)
(43) Application published
4 Feb 1981
(51) INT CL³
C07D 499/00
A61K 31/43
(52) Domestic classification
C2C 1313 1341 1344 1470
1532 1562 1582 1731 213
214 215 220 221 225 226
22Y 246 247 250 251 253
255 256 25Y 28X 292 29Y
30Y 320 321 322 328 32Y
33Y 340 342 34Y 351 352
357 364 366 367 36Y 385
43X 450 45Y 510 511 514
51X 521 52Y 531 535 624
628 635 645 672 678 720
723 746 800 801 80Y AA
KE LA LX MG SC SD YX
A5B 170 180 213 216 21Y
J
(56) Documents cited
EP 0002927A
GB 2000138A
GB 1332306
GB 640713
GB 637184
Nature 278 360-361
DE-OS 2,824535A
(58) Field of search
C2C
(71) Applicants
Bayer Aktiengesellschaft,
509 Leverkusen-
Bayerwerk,
Germany.
(72) Inventors
Karl Metzger,
Ekkehard Niemers,
Hans-Bodo König,
Wilfried Schröck.
(74) Agents
Carpmaels & Ransford

(54) Penicillin 1,1-dioxides

(57) Anti-bacterially active penicillin 1,1-dioxides have the formula



or are pharmaceutically acceptable salts thereof, in which

R₁ denotes a hydrogen atom or an ester-forming radical,

R₂ denotes a hydrogen or bromine atom, an optionally substituted alkoxy radical, an optionally substituted alkylthio radical, an azido radical, an optionally substituted alkyl radical, an optionally substituted cycloalkyl radical, an aryl, aralkyl, heterocyclyl or acyl radical or a caboxyl or cyano group and

R₃ denotes a hydrogen or halogen atom, an azido radical or one of various defined organic radicals.

The compounds are also *inhibitors of* β -lactamases so they can be used in conjunction with β -lactamase-susceptible antibiotics. They are useful in fighting bacterial infection, in promoting animal growth and preserving various materials.

U 2 053 220 A


SPECIFICATION

New penicillanic acid 1,1-dioxide compounds their production and their medicinal use

5 The present invention relates to certain new penicillanic acid 1,1-dioxide compounds, to a process for their production and to their use as medicaments in human medicine and in veterinary medicine and as feed additives, and, in particular, their use as β -lactamase inhibitors. 5

1,1-Dioxides of certain penicillanic acids, for example penicillanic acid 1,1-dioxide can be synthesised and have been recommended as inhibitors of β -lactamases (Nature 278. 360 - 361; and DE-OS (German
10 Published Specification) 2,824,535). 10

According to the present invention we provide compounds which are penicillanic acid 1,1-dioxides of the general formula



or a salt thereof, in which 20

R_1 denotes a hydrogen atom or an ester-forming radical,

R_2 denotes a hydrogen or bromine atom, an optionally substituted alkoxy radical, an optionally substituted alkylthio radical, an azido radical, an optionally substituted alkyl radical, an optionally substituted cycloalkyl
25 radical, an aryl, aralkyl, heterocyclyl or acyl radical or a carboxyl or cyano group and 25

R_3 denotes a hydrogen or halogen atom, an azido radical, an optionally substituted alkyl radical, an optionally substituted alkoxy radical, an optionally substituted cycloalkyl radical, an aralkyl or aryl radical, an optionally substituted alkylthio radical, a heterocyclyl or acyl radical or a radical of the general formula



or
35 R_2 and R_3 together represent a radical of the formula $O=, R_4-O-N=$, 35



but in which 40

R_2 and R_3 cannot simultaneously be hydrogen, azido or acyl,

R_4 denotes an optionally substituted alkyl radical, an optionally substituted cycloalkyl radical, an optionally substituted aralkyl radical or an aryl or heterocyclyl radical,

45 R_5 denotes a hydrogen atom, an optionally substituted alkyl radical, an optionally substituted aralkyl radical, an optionally substituted cycloalkyl radical, an aryl or heterocyclyl radical or an optionally substituted alkylsulphonyl radical, or an arylsulphonyl, heterocyclylsulphonyl or aminosulphonyl radical and 45

R_6 denotes an acyl radical, an hydrogen atom, an optionally substituted alkyl radical, an optionally substituted aralkyl radical or an optionally substituted cycloalkyl radical, an aryl or heterocyclyl radical, or

50 R_5 and R_6 together with the nitrogen atom denote a 4-membered to 7-membered heterocyclic ring, optionally including further hetero-atoms, 50

R_7 and R_8 independently denote a hydrogen atom, an optionally substituted alkyl radical, an aryl radical, an optionally substituted cycloalkyl radical, an aralkyl radical or an optionally substituted amino group or, together with the carbon atom to which they are bonded, denote a 3-membered to 7-membered carbocyclic
55 ring or, including one or more hetero-atoms, a hetero-cyclic ring and 55

R_9 denotes a hydrogen atom, an optionally substituted alkyl radical, an optionally substituted cycloalkyl radical, an aryl, aralkyl or heterocyclyl radical or an optionally substituted alkylsulphonyl radical.


Examples of the ester-forming radicals R_1 are optionally substituted alkyl and optionally substituted aralkyl, aryl and heterocyclyl.

60 The hydrogen atom of R_2 and R_3 is also to be understood, in particular, as the hydrogen isotope deuterium. In the general formula (I), optionally substituted alkyl of R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 and R_9 , is straightchain or branched alkyl with preferably 1 to 6, especially 1 to 4, carbon atoms. Examples which may be mentioned are optionally substituted methyl, ethyl, n- and i-propyl and n-, i- and t-butyl.

Optionally substituted alkyl of R_1 is, for example, C_1 to C_8 alkyl, preferably C_1 to C_3 alkyl, which is optionally
65 mono- di- or tri-substituted, preferably mono-substituted, by a substituent or substituents selected from: a 65

- halogen atom (preferably a fluorine, chlorine, bromine or iodine atom, especially a fluorine, chlorine or bromine atom); amino; mono-lower alkylamino (preferably ethylamino, and, especially, methylamino); di-lower alkylamino (preferably diethylamino, and, especially, dimethylamino); pyrrolidyl; piperidyl; HCO-NH-, lower alkyl-CO-NH- (preferably CH₃-CO-NH-); H-CO-N(lower alkyl)- (preferably H-CO-N(CH₃)- or H-CO-N(C₂H₅)-); lower alkyl-CO-N(lower alkyl), (preferably CH₃-CO-N(CH₃)); (lower alkyl)₂C=N-; lower alkyl-SO₂-NH-, (preferably C₂H₅-SO₂-NH- and, especially, CH₃-SO₂-NH-); lower alkyl-SO₂-N(lower alkyl)-, (preferably CH₃-SO₂-N(CH₃)-); HO-SO₂-NH-; HO-SO₂-N(lower alkyl)-, (preferably HO-SO₂-N-(CH₃)- or HO-SO₂-N(C₂H₅)-); amidino; (lower alkyl)₂-N-CH=N- (especially (CH₃)₂N-CH=N-);


10



10

- guanido; nitro; azido; hydroxyl; lower alkoxy (C₂H₅-O- or, especially, CH₃-O-), H-CO-O-, lower alkyl-CO-O-, (preferably CH₃-CO-O-, C₂H₅-CO-O- or (CH₃)₃C-CO-O-); lower alkyl-O-CO-O- (preferably CH₃-O-CO-O-, C₂H₅-O-CO-O- or (CH₃)₃C-O-CO-O-); H₂N-CO-O-; lower alkyl-NH-CO-O- preferably CH₃-NH-CO-O- or C₂H₅-NH-CO-O-); (lower alkyl)₂N-CO-O- (preferably (CH₃)₂N-CO-O- or (C₂H₅)₂N-CO-O-);

15



15

- H₂N-SO₂-O-; lower alkyl-NH-SO₂-O-, (preferably CH₃-NH-SO₂-O- or C₂H₅-NH-SO₂-O-); (lower alkyl)₂N-SO₂-O-, (preferably (CH₃)₂N-SO₂-O- or (C₂H₅)₂N-SO₂-O-); HOOC-; H₂N-CO-; (lower alkyl)₂N-CO- (especially (CH₃)₂N-CO- or (C₂H₅)₂N-CO-); OHC-; HO-SO₂-O-; HS-; lower alkyl-S-, (preferably CH₃-S-, CF₃-S-, C₂H₅-S- or (CH₃)₂CH-S-); lower alkyl-S- (preferably CH₃-S- or C₂H₅-S-); HO₃S-; lower alkyl-SO₂- (preferably CH₃-SO₂-, CF₃-SO₂- or


20

20

- C₂H₅-SO₂-); H₂N-SO₂-; lower alkyl-NH-SO₂- (preferably CH₃-NH-SO₂- or C₂H₅-NH-SO₂-); (lower alkyl)₂N-SO₂- (preferably (CH₃)₂N-SO₂- or (C₂H₅)₂N-SO₂-);

25

25



30

30

HO-SO₂-S-; heterocyclyl (preferably furyl, thienyl, pyridyl or 2-oxo-benzimidazo-lyl); lower alkylcarbonyl (especially acetyl); benzoyl; lower dialkylamino-lower alkoxy-carbonyloxy, (especially dimethylamino- or diethylamino-C₁ or C₂ alkoxy-carbonyloxy); morpholino-, piperidino- or pyrrolidino-C₁-C₂-alkoxy-carbonyloxy; lower alkoxy-carbonylamino; and lower alkylcarbonylthio.

- Optionally substituted cycloalkyl of R₂, R₃, R₄, R₅, R₆, R₇, R₈ and R₉ is monocyclic, bicyclic or tricyclic and preferably contains 3 to 10, especially 3, 5 or 6, carbon atoms. Examples which may be mentioned are optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl and adamantyl.

35

35

- Optionally substituted aryl of R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, and R₉ is aryl with preferably 6 to 10 carbon atoms in the aryl part. Examples which may be mentioned are optionally substituted phenyl or naphthyl. Substituents in the phenyl ring are in the o-, m- or p- position.

40

40

- Optionally substituted aralkyl of R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ and R₉ is aralkyl which is optionally substituted in the aryl part and/or alkyl part and has preferably 6 or 10, especially 6, carbon atoms in the aryl part and preferably 1 to 4, especially 1 or 2, carbon atoms in the alkyl part, it being possible for the alkyl part to be straight-chain or branched. Examples which may be mentioned are optionally substituted benzyl and phenylethyl.

45

45


- Optionally substituted heterocyclyl of R₁, R₂, R₃, R₄, R₅, R₆ and R₉ is a hetero-paraffinic, hetero-aromatic or hetero-olefinic 5-membered to 7-membered, preferably 5-membered or 6-membered, ring with preferably 1 to 3, especially 1 or 2, identical or different hetero-atoms. Hetero-atoms are oxygen, sulphur or nitrogen.

- Examples which may be mentioned are optionally substituted thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, sydnonyl, oxtriazolyl, thia-triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, tetrahydrofuranyl, dioxanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyron-2-yl and pyron-4-yl, 2-oxo-tetrahydro-fur-5-yl and 2-oxo-2,5-dihydrofur-5-yl. The above-mentioned heterocyclic radicals can be fused to carbocyclic rings or other heterocyclic rings, and in particular they can be benzo-fused. Examples which may be mentioned are

55

55

60



60

- The above-mentioned alkyl, cycloalkyl, aryl and aralkyl radicals can carry one or more, preferably 1 to 3 and especially 1 or 2, identical or different radicals, preferably those defined as R₁₀ below.

65


65

The radicals mentioned which are unsubstituted or contain one substituent R_{10} are very particularly preferred.


Heterocyclyl can carry one or more, preferably 1 to 3 and especially 1 or 2, identical or different radicals, preferably those defined as R_{11} below. Heterocyclyl which is unsubstituted or contains one substituent R_{11} is very particularly preferred.

In the following explanations, the expression "lower alkyl" denotes straight-chain or branched alkyl with preferably 1 to 6, especially 1 to 4, carbon atoms in all cases, also in association with other atoms or groups (for example lower alkoxy, NCON-(lower alkyl) and the like). Examples which may be mentioned are optionally substituted methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. "Lower alkyl" can be substituted by 1 to 5, especially 1 to 3, identical or different halogen atoms, halogen atoms being, preferably, fluorine, chlorine and bromine, especially fluorine and chlorine. Examples which may be mentioned are tri-fluoromethyl, chloro-difluoromethyl, bromomethyl, 2,2,2-trifluoroethyl and pentafluoroethyl.

R_{10} denotes a halogen atom (preferably a fluorine, chlorine, bromine or iodine atom, especially a fluorine, chlorine or bromine atom); amino; mono-lower alkylamino (preferably ethylamino and, especially, methylamino); di-lower alkylamino (preferably diethylamino and, especially, dimethylamino); pyrrolidyl; piperidyl; HCO-NH-; lower alkyl-CO-NH- (preferably CH₃-CO-NH-); H-CO-N(lower alkyl)- (preferably H-CO-N(CH₃)- or H-CO-N(C₂H₅)-); di-lower alkylamino-lower alkyl; lower alkyl-CO-N(lower alkyl)- (preferably CH₃-CO-N(CH₃)-); (lower alkyl)₂C=N-; lower alkyl-SO₂-NH- (preferably C₂H₅-SO₂-NH- and, especially, CH₃-SO₂-NH-); lower alkyl-SO₂-N(lower alkyl)- (preferably CH₃-SO₂-N(CH₃)-); HO-SO₂-NH-; HO-SO₂-N(lower alkyl)- (preferably HO-SO₂-N(CH₃)- or HO-SO₂-N(C₂H₅)-); amidino; (lower alkyl)₂-N-CH=N- (in particular (CH₃)₂N-CH=N-);




guanido; nitro; azido; hydroxyl; lower alkoxy, (preferably C₂H₅-O-, and, especially, CH₃-O-); H-CO-O-; lower alkyl-CO-O- (preferably CH₃-CO-O-, C₂H₅-CO-O- or (CH₃)₃C-CO-O-); lower alkyl-O-CO-O- (preferably CH₃-O-CO-O-, C₂H₅-O-CO-O- or (CH₃)₃C-O-CO-O-); H₂N-CO-O-; lower alkyl-NH-CO-O- (preferably CH₃-NH-CO-O- or C₂H₅-NH-CO-O-); (lower alkyl)₂N-CO-O- (preferably (CH₃)₂N-CO-O- or (C₂H₅)₂N-CO-O-);




H₂N-SO-O-; lower alkyl-NH-SO₂-O- (preferably CH₃-NH-SO₂-O- or C₂H₅-NH-SO₂-O-); (lower alkyl)₂N-SO₂-O- (preferably (CH₃)₂N-SO₂-O- or (C₂H₅)₂N-SO₂-O-); HOOC-; H₂N-CO-; (lower alkyl)₂N-CO- (especially (CH₃)₂N-CO- and (C₂H₅)₂N-CO-); OHC-; HO-SO₂-O-; HS-; lower alkyl-S- (preferably CH₃-S-, CF₃-S-, C₂H₅-S- or (CH₃)₂CH-S-); lower alkyl-S- (preferably CH₃-S- or C₂H₅-S-); HO₃S-; lower alkyl-SO₂- (preferably CH₃-SO₂-,

CF₃SO₂- or C₂H₅-SO₂-); H₂N-SO₂-; lower alkyl-NH-SO₂- (preferably CH₃-NH-SO₂- or C₂H₅-NH-SO₂-); (lower alkyl)₂N-SO₂- (preferably (CH₃)₂N-SO₂- or (C₂H₅)₂N-SO₂-);



HO-SO₂-S-; straight-chain or branched alkyl with 1 to 6 carbon atoms (preferably ethyl, propyl, isopropyl, n-butyl, sec.-butyl or tert.-butyl, and, especially, methyl); phenyl; or phenoxy.

Possible substituents of the alkyl groups of R_2 and R_3 are furthermore oxo and groups of the formulae R_4 -C-N= and




wherein

R_4 , R_5 and R_6 have the meaning given.

In the case where R_{11} is on one or more carbon atoms in the heterocyclyl radical, R_{11} denotes lower alkyl, (preferably ethyl or isopropyl, and especially, methyl); trifluoromethyl; a halogen atom (preferably a fluorine, chlorine or bromine atom); amino; lower alkylamino (preferably CH₃-NH- or C₂H₅-NH-); di-lower alkylamino (preferably (CH₃)₂N- or (C₂H₅)₂N-); formyl-amino; acetyl-amino; CH₃-O-CO-NH-; C₂H₅O-CO-NH-; CH₃-SO₂-NH-; hydroxyl; methoxy; ethoxy; methylthio; ethylthio; CH₃-SO₂-; CH₃-SO-; HOOC-; HO₃S-; HCO-; lower alkyl-CO-, (preferably CH₃-CO-); lower alkyl-O-CO-, (preferably CH₃-O-CO- or C₂H₅O-CO-); -CN; the oxo group =O; the thiono group =S; or the imino group =NH.

In the case where R_{11} in a nitrogen-containing heterocyclyl radical is a substituent on one or more nitrogen atoms, R_{11} denotes lower alkyl, (preferably propyl or isopropyl, and, especially, methyl or ethyl); -C=N-; -CHO-; -COO-lower alkyl (preferably -COO-CH₃, -COOC₂H₅, -COOCH(CH₃)₂ or -COO-C(CH₃)₃); -CO-NH₂; -CO-NH-lower alkyl (preferably -CO-NH-CH₃, -CO-NH-C₂H₅ or -CO-NH-CH(CH₃)₂); or -CO-lower alkyl (preferably -CO-CH₃, -CO-C₂H₅ or -CO-CH(CH₃)₂).

The rings which can be formed by R_7 and R_8 , together with the carbon atom to which they are bonded, are saturated or unsaturated. Unsaturated rings preferably contain 1 or 2 double bonds. The rings can contain 1 or more, preferably 1 or 2 and especially 1, hetero-atoms or hetero-groups. Hetero-atoms which may be mentioned are oxygen, sulphur and/or nitrogen. Examples of hetero-groups which may be mentioned are the SO_2 group and the lower alkyl-N group, and in the case of 6-rings, one hetero-atom or one hetero-group is preferably in the 4-position (relative to the carbon atom to which R_7 and R_8 are bonded). Particularly preferred rings which may be mentioned are:



The rings which can be formed by R_5 and R_6 , together with the nitrogen atom to which they are bonded, are saturated or unsaturated; unsaturated rings preferably contain 1 or 2 double bonds. The rings can contain a further 1 or 2 hetero-atoms, in particular 1 further hetero-atom, for example oxygen, sulphur or nitrogen, also in the form of SO_2 groups or lower alkyl-N groups. Piperidino, morpholino, pyrrolidino, pyrrolino, piperazino and N'-lower alkyl-piperazino may be mentioned as preferred.

The rings which are formed by R_7 and R_8 or R_5 and R_6 , together with the carbon atom or nitrogen atom to which they are bonded, can contain one or more, preferably 1 to 3, especially 1 or 2, identical or different substituents preferably selected from, a halogen atom (preferably a fluorine, chlorine or bromine atom); oxo; hydroxyl, lower alkoxy, (preferably methoxy or ethoxy); lower alkylthio, (preferably methylthio or ethylthio); amino; lower alkylamino, (preferably CH_3-NH- or C_2H_5-NH-); di-lower alkylamino (preferably dimethylamino or diethylamino); $-CN$; $-COOH$; $-COOCH_3$; $-COOC_2H_5$; and straight-chain or branched lower alkyl (preferably methyl or ethyl).

Optionally substituted alkoxy of R_2 and R_3 is, for example, alkoxy which has 1 to 6, especially 1 to 3, carbon atoms and is optionally monosubstituted or polysubstituted, preferably monosubstituted, preferably by R_{10} as defined above.

Optionally substituted alkylthio or R_2 and R_3 and alkylsulphonyl of R_5 and R_6 are, for example, alkylthio or alkylsulphonyl which has 1 to 6, especially 1 to 3, carbon atoms and can be monosubstituted or polysubstituted, preferably monosubstituted, preferably by R_{10} as defined above.

Acyl of R_2 , R_3 and R_6 is, especially, optionally substituted alkylcarbonyl, arylcarbonyl or aralkylcarbonyl, optionally substituted cycloalkylcarbonyl or a corresponding sulphonyl radical, and furthermore optionally substituted alkoxy carbonyl or optionally substituted aminocarbonyl, alkyl, aralkyl, aryl, cycloalkyl, alkoxy and amino corresponding to the above-mentioned definitions.

Optionally substituted amino is NH_2 or mono- or di-substituted amino, possible substituents being optionally substituted alkyl or aryl, optionally substituted aralkyl or heterocyclyl or optionally substituted cycloalkyl, the meaning of the substituents on the amino corresponding to the above-mentioned definitions for the individual radicals.

Optionally substituted arylsulphonyl, hetero-cyclylsulphonyl and aminosulphonyl correspond to the above-mentioned definitions with regard to aryl, heterocyclyl and amino.

Preferred compounds of the present invention are those of the general formula (II)

oxidation, these groups are split off again in the customary manner.

The compounds of the present invention display an antimicrobial activity, coupled with low toxicity. These properties enable them to be used as chemotherapeutic active compounds in medicine and as substances for preserving inorganic and organic materials, especially organic materials of all kinds, for example polymers, lubricants, paints, fibres, leather, paper and timber, and foodstuffs and water.

Examples of micro-organisms against which the active compounds of the present invention have an action are Micrococcaceae, such as Staphylococci, for example *Staphylococcus aureus*, *Staphylococcus epidermidis* and *Staphylococcus aerogenes*, and *Gasskya tetragena*; Lactobacteriaceae, such as Streptococci, for example *Streptococcus pyogenes*, and *Diplococcus pneumoniae*; Neisseriaceae, such as Neisseriae, for example *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis* and *Neisseria flava*; and Bacillaceae, such as aerobic spore-forming Bacillaceae, for example *Bacillus anthracis*, *Bacillus subtilis* and *Bacillus cereus*.

The above list of pathogens is purely illustrative.

As stated above, the invention also relates to the use in human and veterinary medicine in combating bacterial diseases of the compounds of the invention.

The present invention provides a pharmaceutical composition containing as active ingredient a compound of the invention in admixture with a solid or liquefied gaseous diluent, or in admixture with a liquid diluent other than a solvent of a molecular weight less than 200 (preferably less than 350) except in the presence of a surface active agent.

The invention further provides a pharmaceutical composition containing as active ingredient a compound of the invention in the form of a sterile and/or physiologically isotonic aqueous solution.

The invention also provides a medicament in dosage unit form comprising a compound of the invention.

The invention also provides a medicament in the form of tablets (including lozenges and granules), dragees, capsules, pills, ampoules or suppositories comprising a compound of the invention.

"Medicament" as used in this specification means physically discrete coherent portions suitable for medical administration "Medicament in dosage unit form" as used in this Specification means physically discrete coherent units suitable for medical administration each containing a daily dose or a multiple (up to four times) or submultiple (down to a fortieth) of a daily dose of the compound of the invention in association with a carrier and/or enclosed within an envelope. Whether the medicament contains a daily dose or, for example, a half, a third or a quarter of a daily dose will depend on whether the medicament is to be administered once or, for example, twice, three times or four times a day respectively.

The pharmaceutical composition according to the invention may, for example, take the form of ointments, gels, pastes, creams, sprays (including aerosols), lotions, suspensions, solutions and emulsions of the active ingredient in aqueous or non-aqueous diluents, syrups, granulates or powders.

The diluents to be used in pharmaceutical compositions (e.g. granulates) adapted to be formed into tablets, dragees, capsules and pills include the following: (a) fillers and extenders, e.g. starch, sugars, mannitol, and silicic acid; (b) binding agents, e.g. carboxymethyl cellulose and other cellulose derivatives, alginates, gelatine and polyvinyl pyrrolidone; (c) moisturizing agents, e.g. glycerol; (d) disintegrating agents, e.g. agar-agar, calcium carbonate and sodium bicarbonate; (e) agents for retarding dissolution e.g. paraffin; (f) resorption accelerators, e.g. quaternary ammonium compounds; (g) surface active agents, e.g. cetyl alcohol, glycerol monostearate; (h) adsorptive carriers, e.g. kaolin and bentonite; (i) lubricants, e.g. talc, calcium and magnesium stearate and solid polyethyl glycols.

The tablets, dragees, capsules and pills formed from the pharmaceutical compositions of the invention can have the customary coatings, envelopes and protective matrices, which may contain opacifiers. They can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time. The coatings, envelopes and protective matrices may be made, for example, of polymeric substances or waxes.

The ingredient can also be made up in microencapsulated form together with one or several of the above-mentioned diluents.

The diluents to be used in pharmaceutical compositions adapted to be formed into suppositories can, for example, be the usual water-soluble diluents, such as polyethylene glycols and fats (e.g. cocoa oil and high esters (e.g. C₁₄-alcohol with C₁₆-fatty acid) or mixtures of these diluents.

The pharmaceutical compositions which are ointments, pastes, creams and gels can, for example, contain the usual diluents, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.

The pharmaceutical compositions which are powders and sprays can, for example, contain the usual diluents, e.g. lactose, talc, silicic acid, aluminium hydroxide, calcium silicate, and polyamide powder or mixtures of these substances. Aerosol sprays can, for example, contain the usual propellants, e.g. chlorofluorohydrocarbons.

The pharmaceutical compositions which are solutions and emulsions can, for example, contain the customary diluents (with, of course, the above-mentioned exclusion of solvents having a molecular weight below 200 except in the presence of a surface-active agent), such as solvents, dissolving agents and emulsifiers; specific examples of such diluents are water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (for example ground nut oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid

esters of sorbitol or mixtures thereof.

For parenteral administration, solutions and emulsions should be sterile, and, if appropriate, blood-isotonic.

The pharmaceutical compositions which are suspensions can contain the usual diluents, such as liquid
5 diluents, e.g. water, ethyl alcohol, propylene glycol, surface-active agents (e.g. ethoxylated isostearyl
alcohols, polyoxyethylene sorbite and sorbitane esters), micro-crystalline cellulose, aluminium metahydrox- 5
ide, bentonite, agar-agar and tragacanth or mixtures thereof.

All the pharmaceutical compositions according to the invention can also contain colouring agents and
preservatives as well as perfumes and flavouring additions (e.g. peppermint oil and eucalyptus oil) and
10 sweetening agents (e.g. saccharin). 10

The pharmaceutical compositions according to the invention generally contain from 0.1 to 99.5%, usually
from 0.5 to 95% of the active ingredient by weight of the total composition.

In addition to a compound of the invention, the pharmaceutical compositions and medicaments according
to the invention can also contain other pharmaceutically active compounds. They may also contain a
15 plurality of compounds of the invention. 15

Any diluent in the medicaments of the present invention may be any of those mentioned above in relation
to the pharmaceutical compositions of the present invention. Such medicaments may include solvents of
molecular weight less than 200 as sole diluent.

The discrete coherent portions constituting the medicament according to the invention will generally be
20 adapted by virtue of their shape or packaging for medical administration and may be, for example, any of the 20
following: tablets (including lozenges and granulates), pills, dragees, capsules, suppositories and ampoules.
Some of these forms may be made up for delayed release of the active ingredient. Some, such as capsules,
include a protective envelope which renders the portions of the medicament physically discrete and
coherent.

The preferred daily dose for administration of the medicaments of the invention is 500 mg to 10 g of active
25 ingredient. 25

The product of the above-mentioned pharmaceutical compositions and medicaments is carried out by any
method known in the art, for example, by mixing the active ingredient(s) with the diluent(s) to form a
pharmaceutical composition (e.g. a granulate) and then forming the composition into the medicament (e.g.
30 tablets). 30

This invention further provides a method of combating (including prevention, relief and cure of) the
above-mentioned diseases in human and non-human animals, which comprises administering to the
animals a compound of the invention alone or in admixture with a diluent or in the form of a medicament
according to the invention.

It is envisaged that these active compounds will be administered perorally, parenterally (for example
35 intramuscularly, intraperitoneally, subcutaneously and intravenously), rectally or locally, preferably orally or 35
parenterally, especially intravenously or intramuscularly. Preferred pharmaceutical compositions and
medicaments are therefore those adapted for administration such as oral or parenteral administration.
Administration in the method of the invention is preferably oral or parenteral administration.

In general it has proved advantageous to administer amounts of from 5 mg to 1,000 mg/kg, preferably 10
40 mg to 200 mg/kg, of body weight per day, optionally in the form of several individual administrations, to 40
achieve effective results. An individual administration preferably contains the active compound or
compounds according to the invention in amounts of 1 mg to 250 mg/kg, in particular 10 mg to 100 mg/kg, of
body weight. Nevertheless, it can at times be necessary to deviate from those dosage rates, and in particular
45 to do so as a function of the nature and body weight of the human or animal subject to be treated, the 45
individual reaction of this subject to the treatment, the type of formulation in which the active ingredient is
administered and the mode in which the administration is carried out, and the point in the progress of the
disease or interval at which it is to be administered. Thus it may in some case suffice to use less than the
above-mentioned minimum dosage rate, whilst other cases the upper limit mentioned must be exceeded to
50 achieve the desired results. Where larger amounts are administered it can be advisable to divide these into 50
several individual administrations over the course of the day.

The new penicillanic acid 1,1-dioxide derivatives of the present invention are distinguished by an
antibacterial action, which has been tested *in vivo* and by oral resorbability.

In order to broaden the spectrum of action and to achieve a more powerful action, especially in the case of
55 bacteria which form β -lactamase, the penicillanic acid 1,1-dioxide derivatives according to the invention can 55
be combined with other antimicrobial active compounds, for example with β -lactam antibiotics, such as
penicillins.

In order to broaden the spectrum of action and to achieve a more powerful action, the penicillanic acid
1,1-dioxide derivatives according to the invention can also be combined with aminoglycoside antibiotics,
60 such as gentamicin, canamycin, sisomicin, amikacin or tobramycin. 60

The penicillanic acid 1,1-dioxide derivatives according to the invention inactivate, by inhibition or
destruction, the bacterial enzymes which split the β -lactam ring (β -lactamases). The degradation of other
penicillins, for example of amoxicillin, mezlocillin, ampicillin, azlocillin, penicillin G, carbenicillin and
ticarcillin, is thereby prevented and on the one hand they thereby retain their activity and on the other hand
65 their spectrum of action is thereby extended to bacteria which produce β -lactamase. This is demonstrated in 65

Table 1 with the aid of the improvement in the minimum inhibitory concentrations (MIC).

TABLE 1

| | | | | | |
|----|----------------------------|-----|-------|-----|----|
| 5 | MIC in E/ml | | | | 5 |
| | Bacteria strain | A | B | C | |
| | E. coli T 7 | 256 | 64+64 | 256 | |
| 10 | Klebsiella pneum. 1852 | 128 | 64+64 | 256 | 10 |
| | Staphylococcus aureus 1756 | 256 | 64+64 | 256 | |

A = mezlocillin; B = mezlocillin + compound according to Example 1; C = compound according to Example 1.


Table 1 shows the improvement (equivalent to lowering) of the minimum inhibitory concentrations (MIC) of mezlocillin in the case of strains which are otherwise resistant towards mezlocillin.

In vitro experiments

The compound of Example 1, which can be regarded as a typical representative of the compounds according to the invention, was diluted with Müller-Hinton nutrient broth to a content of 100 µg/ml, 0.1% of glucose being added. The nutrient solution contained in each case one x 10⁵ to two x 10⁵ bacteria per ml. The test-tubes containing this batch were in each case incubated for 24 hours and the degree of turbidity was then determined. Absence of turbidity indicates action. At a dosage of 1 µg/ml, the bacteria cultures inoculated with Staphylococcus aureus 133 were free from turbidity.

The following Examples illustrate processes for the production of compounds of the present invention.


Example 1



6-Aminopenicillanic acid 1,1-dioxide

11.7 g of sodium 6-benzyloxycarbonylaminopenicillanate 1,1-dioxide were dissolved in 100 ml of water. The pH was adjusted to 6.5 by adding a little dilute hydrochloric acid and methanol was then added in an amount such that a clear solution is obtained (~40 ml). This solution was added to a suspension of 11.7 g of palladium black in 240 ml of water (pre-hydrogenated for one hour). Hydrogenation was then carried out under normal pressure for 2½ hours. Thereafter, the catalyst was filtered off and the filtrate was adjusted to pH 3.5, concentrated a little on a rotary evaporator in order to remove the methanol and then freeze-dried. The residue was dissolved in a little methanol and re-precipitated by adding ether. The precipitate was filtered off and washed with ether. After purification on an ion exchanger column, 5.8 g of 6-amino-


Example 2



6-Benzyloxycarbonylaminopenicillanic acid 1,1-dioxide

18.6 g (0.05 mol) of sodium 6-benzyloxycarbonylaminopenicillanate were dissolved in 260 ml of water. A solution of 9.5 g of potassium permanganate in 300 ml of water was added at 0° - 5°C and at pH 6 - 7.5 in the course of one hour. Excess permanganate was then destroyed by adding bisulphite solution and the mixture was filtered over kieselguhr. The filtrate was adjusted to pH 2 and extracted twice with ethyl acetate. The organic phase was dried with anhydrous Na₂SO₄ and concentrated. The residue was dissolved in methanol, and an equimolar amount of sodium caprylate solution (ether/methanol) was added. A precipitate formed and was filtered off and washed with ether. 12 g (59% of theory) of sodium 6-benzyloxy-

Example 3



A solution of 2.05g of KMnO_4 in 50 ml of water and 0.68 ml of 58% strength phosphoric acid were added dropwise to a solution, cooled to 0°C , of 3.3 g of sodium 6-mesyloxy-6,6-dimethyl-2-oxo-1,4-dihydro-5H-1,2,4-oxadiazepine-3-carboxylate in 30 ml of water (adjusted to pH 7.0 - 7.5 by means of 1 N NaOH) in the course of about 20 minutes. During this addition, the temperature was kept below 10°C and the pH was kept at 6 - 7.5 by means of 10% strength phosphoric acid. The mixture was then stirred for a further 10 minutes, the excess KMnO_4 was removed with a little bisulphite solution and the precipitate was filtered off over celite and washed with water. The combined aqueous solutions were covered with a layer of ethyl acetate, the mixture was acidified to pH 2 with 2 N HCl, whilst stirring, and, after separating off the organic phase, the aqueous phase was extracted a further three times by shaking with ethyl acetate. After distilling off the solvent from the combined dried ethyl acetate extracts, mesyloxy-6,6-dimethyl-2-oxo-1,4-dihydro-5H-1,2,4-oxadiazepine-3-carboxylic acid was left as an oil, which crystallised, however, on trituration with ether. The needle-shaped crystals were filtered off, washed with ether and dried.

Yield: 1.0 g

NMR (CD_3OD ; δ ; 60 MHz): 5.55 (d, 1H); 5.1 (d, 1H); 4.5 (s, C-3H); 3.1 (s, 3H); 1.6 (s, 3H) and 1.45 (s, 3H) ppm.


After dissolving the product in methanol and adding sodium 2-ethylhexanoate in methanol-containing ether (about 1 molar), the sodium salt could be precipitated with ether.

NMR (CD_3OD ; δ ; 60MHz): 6.1 (d; 1H); and 5.25 (d; 1H) ppm.

The 6-mesyloxy-6,6-dimethyl-2-oxo-1,4-dihydro-5H-1,2,4-oxadiazepine-3-carboxylic acid used as the starting material was initially obtained as the free acid (foam) from disilylated 6-aminopenicillanic acid and mesyl chloride in chloroform in the presence of triethylamine (1 hour at 0°C ; 30 minutes at 20°C). The sodium salt was obtained from the free acid by dissolving in water/sodium hydroxide solution (at pH 7) and freeze-drying the solution.

NMR (CD_3OD ; δ ; 60MHz): 5.4 (d; 1H), 5.1 (d; 1H); 4.0 (s; C-3H); and 2.9 (s; 3H) ppm.

Example 4




This compound was obtained from 2.2 g of 6-tolylaminopenicillanic acid in the manner described in

Example 1.

Yield: 1.6 g


NMR (CD_3OD , δ , 60MHz): 7.8 (d; aromatic H); 7.3H (d; aromatic H); 5.5 (d; 1H); 4.85 (d; 1H); 4.4 (s; C-3H); 2.4 (s; 3H); 1.5 (s; 3H); and 1.35 (s; 3H) ppm.

Example 5



8.3 g of 6-(dimethylaminomethyleneamino)-penicillanic acid were dissolved in 50 ml of water. 180 ml of 0.2 molar KMnO_4 solution were added dropwise at 0 to 50°C and at a pH of 6 to 7.5. The reaction mixture was subsequently stirred for 15 minutes and then filtered over kieselguhr. The filtrate was freeze-dried and the residue was purified by chromatography. 5.2 g of 6-(dimethylaminomethyleneamino)-penicillanic acid 1,1-dioxide were obtained.

The following compounds were also obtained in the manner described in Example 5:



5


5

Example

 R_3 R_2

10


6



H

10


7



H

15

8




H

15

20


9



H

20

10

 OCH_3


25

25

Example 11

30

30



35


35





This penicillanic acid S-dioxide was prepared in 54% yield from 2 g of 6- β -pyrrolidine-2,5-dione-1-yl-penicillanic acid in the manner described in Example 2. NMR signals at $\tau = 4.1$ (1H), 4.9 (1H), 5.6 (1H), 7.4 (4H) and 8.6 (6H) ppm.


40

40

The following compounds were obtained in the manner described Example 2:




| | R ₃ | R ₂ | |
|----|--|-----------------------|----|
| 5 | 12.  | H OCH ₃ | 5 |
| | 13. " | | |
| 10 | 14.  | H OCH ₃ | 10 |
| | 15. " | | |
| 15 | 16.  | H OCH ₃ | 15 |
| | 17. " | | |
| 20 | 18.  | OCH ₃ | 20 |

25 *Example 19*


35 This penicillanic acid S-dioxide was obtained in 48% yield from 3.5 g of 6-β-phthaloyliminopenicillanic acid in the manner described in Example 2.

NMR signals at τ = 2.15 (4H), 4.1 (1H), 4.9 (1H), 5.5 (1H) and 8.6 (6H) ppm.

40 *Example 20*

45 This penicillanic acid S-dioxide was obtained on 40% yield from 3 g of 6-β-(4,5-benzoisothiazolin-3-one-S-dioxide-2-yl)-penicillanic acid in the manner described in Example 2.

NMR signals at τ = 1.8 - 2.6 (4H), 4.1 (1H), 4.9 (1H), 5.5 (1H) and 8.6 (6H) ppm.

50 *Example 21*60 *6-β-Isopropylamino-penicillanic acid S-dioxide*

60 The pH of 4.4 g of 6-β-isopropylamino-penicillanic acid in 75 ml of water was adjusted to 7 with 5% strength NaOH and the mixture was cooled to 0°C. 2.4 g of KMnO₄ and 0.8 ml of 85% strength phosphoric acid in 60 ml of water were gradually added in a manner such that the internal temperature was kept below 10°C and the pH was kept between 6 and 7.5 (with NaOH or 10% strength H₃PO₄). The mixture was subsequently stirred for 10 minutes and filtered over cellite and a further 0.47 g of KMnO₄ and 0.15 ml of phosphoric acid in 12 ml of water was added at ≤ 10°C and the mixture was subsequently stirred again for 10

65

minutes and filtered over celite and the filtrate was adjusted to pH 6 with 1 N HCl. It was then freeze-dried.

Yield: 5.2 g (61% pure according to the analysis, corresponding to a yield of 73%).

NMR signals at τ = 4.95 (1H), 5.09 (1H), 5.7 (1H) 7.0 (1H), 8.4 (3H), 8.6 (3H) and 8.9 (6H) ppm.

The following penicillanic acid S-dioxides were obtained in the same manner:

| | | | | | |
|----|-----|-------------------------------------|---|------------------|----|
| 5 | | | | | 5 |
| | | | | | |
| 10 | | | | | 10 |
| | | R ₅ | R ₉ | R ₂ | |
| 15 | 22. | | CH ₃ CO- | H | 15 |
| 20 | 23. | " | | H | 20 |
| | 24. | " | | H | |
| 25 | 25. | | | H | 25 |
| | 26. | | CH ₃ SO ₂ - | H | |
| | 27. | CH ₃ SO ₂ - | CH ₃ SO ₂ - | H | |
| 30 | 28. | CH ₃ CH ₂ CO- | CH ₃ CH ₂ SO ₂ - | H | 30 |
| | 29. | | CH ₃ SO ₂ - | H | |
| 35 | 30. | | H | OCH ₃ | 35 |

40 Among the new penicillanic acid 1,1-dioxide salts of the invention, those salts that are pharmaceutically acceptable are particularly important and are preferred. 40


The new free penicillanic acid 1,1-dioxides of the general formula I and their salts can be interconverted in any suitable manner; methods for such interconversion are known in the art.

45 The present invention also comprises pharmaceutically acceptable bioprecursors of the active compounds of the present invention. 45

For the purposes of this specification the term 'pharmaceutically acceptable bioprecursor' of an active compound of the invention means a compound having a structural formula different from the active compound but which nonetheless, upon administration to an animal or human being is converted in the patient's body to the active compound.

50 CLAIMS 50

1. Compounds which are penicillanic acid 1,1-dioxides of the general formula



65 R₁ denotes a hydrogen atom or an ester-forming radical, 65

R_2 denotes a hydrogen or bromine atom, an optionally substituted alkoxy radical, an optionally substituted alkylthio radical, an azido radical, an optionally substituted alkyl radical, an optionally substituted cycloalkyl radical, an aryl, aralkyl, heterocyclyl or acyl radical or a carboxyl or cyano group and

R_3 denotes a hydrogen or halogen atom, an azido radical, an optionally substituted alkyl radical, an optionally substituted alkoxy radical, an optionally substituted cycloalkyl radical, an aralkyl or aryl radical, an optionally substituted alkylthio radical, a heterocyclyl or acyl radical or a radical of the general formula



or

R_2 and R_3 together represent a radical of the formula $O=$, $R_4-O-N=$,



in which

R_2 and R_3 cannot simultaneously be hydrogen, azido or acyl, 20

R_4 denotes an optionally substituted alkyl radical, an optionally substituted cycloalkyl radical, an optionally substituted aralkyl radical or an aryl or heterocyclyl radical,


R_5 denotes a hydrogen atom, an optionally substituted alkyl radical, an optionally substituted aralkyl radical, an optionally substituted cycloalkyl radical, an aryl or heterocyclyl radical or an optionally substituted alkylsulphonyl radical or an arylsulphonyl, heterocyclylsulphonyl or aminosulphonyl radical, and 25

R_6 denotes an acyl radical, a hydrogen atom, an optionally substituted alkyl radical an optionally substituted aralkyl radical or an optionally substituted cycloalkyl radical, an aryl or heterocyclyl radical, or

R_5 and R_6 together with the nitrogen atom denote a 4-membered to 7-membered heterocyclic ring, optionally including further heteroatoms,


R_7 and R_8 independently denote a hydrogen atom, an optionally substituted alkyl radical, an aryl radical, an optionally substituted cycloalkyl radical, an aralkyl radical or an optionally substituted amino group, or, together with the carbon atom to which they are bonded, denote a 3-membered to 7-membered carbocyclic ring or, including one or more hetero-atoms, a heterocyclic ring and R_9 denotes a hydrogen atom, an optionally substituted alkyl radical, an optionally substituted cycloalkyl radical, an aryl, aralkyl or heterocyclyl radical or an optionally substituted alkylsulphonyl radical. 35

2. Compounds according to claim 1, of the general formula




45 in which


R_{12} denotes a hydrogen atom, a sodium ion,



60 R_{13} denotes a hydrogen atom or a methoxy group,
 R_{14} denotes a hydrogen atom,
 R_{15} denotes a hydrogen or SO_2-R_{17} or,
 R_{15} together with R_{14} denotes $=CH-R_{16}$, 60



- 5 R_{17} denotes a C_1 to C_4 alkylsulphonyl radical or a phenyl radical which is optionally substituted by chlorine, bromine, methyl, methoxy, nitro or carboxyl and
 R_{18} and R_{19} independently denote a hydrogen atom or a C_1 to C_4 alkyl group, or together denote a C_4 to C_6 alkylidene radical. 5
- 10 3. 6- β -Chloropenicillanic acid S-dioxide. 10
 4. 6-Dibromopenicillanic acid S-oxide.
 5. 6- α - and 6- β -(1-hydroxyethyl)-penicillanic acid S-dioxide or the corresponding sulphuric acid half-ester thereof
 6. 6- β -Phthalimidopenicillanic acid S-dioxide.
 15 7. 6- β -Succinimidopenicillanic acid S-dioxide. 15
 8. 6- β -Saccharinylpenicillanic acid S-oxide.
 9. 6- α -Methoxy-6- β -succinimidopenicillanic acid S-oxide.
 10. Compounds according to claim 1 which are hereinbefore specifically mentioned other than those according to claims 3 to 9.
- 20 11. A process for the production of a compound according to any of claims 1 to 10 in which a compound of the general formula 20



- 25 in which 25
- 30 R_1 , R_2 and R_3 have the same meaning as in claim 1, is oxidised in a solvent. 30
 12. A process according to claim 11 in which the reaction is carried out in a polar solvent.
 13. A process according to claim 11 or 12 in which the reaction is carried out at a temperature between -20 and +50°C.
 35 14. A process according to any of claims 11 to 13 in which the reaction is carried out at a pH value between 2 and 8. 35
 5. A process according to any of claims 11 to 14 in which the oxidising agent is potassium permanganate, ozone, hydrogen peroxide, hydrogen peroxide in the presence of ammonium molybdate, hydrogen peroxide in glacial acetic acid, an organic peracid, chromium trioxide, ruthenium tetroxide, nitric acid or
 40 N-chlorosuccinimide in methanol/water. 40
 16. A process for the production of a compound according to claim 1 substantially as hereinbefore described in any of Examples 1 to 30.
 17. Compounds according to claim 1 whenever prepared by a process according to any one of claims 11 to 16.
 45 18. A pharmaceutical composition containing as an active ingredient a compound according to any one of claims 1 to 10 and 17 in admixture with a solid or liquefied gaseous diluent or in admixture with a liquid diluent other than a solvent of a molecular weight less than 200 except in the presence of a surface-active agent. 45
 19. A pharmaceutical composition containing as an active ingredient a compound according to any one of claims 1 to 10 and 17 in the form of a sterile or physiologically isotonic aqueous solution. 50
 20. A composition according to claim 18 or 19 containing from 0.5 to 95% by weight of the said active ingredient. 50
 21. A medicament in dosage unit form comprising a compound according to any one of claims 1 to 10 and 17.
 55 22. A medicament in the form of tablets, pills, dragees, capsules, ampoules or suppositories comprising a compound according to any one of claims 1 to 10 and 17. 55
 23. A method of combating bacterial infections in human and non-human animals which comprises administering to the animals an active compound according to any one of claims 1 to 10 and 17 either alone or in admixture with a diluent or in the form of a medicament according to claim 21 or 22.
 60 24. A method according to claim 23 in which the active compound is administered in an amount of 10 to 200 mg per kg body weight per day. 60
 25. A method according to claim 23 or 24 in which the active compound is administered orally or parenterally.
 26. A β -lactam antibiotic having had its activity increased by being admixed with a compound according to claim 1. 65

-
27. A β -lactam antibiotic which is unstable towards β -lactamase having had its activity increased by being admixed with a compound according to claim 1.
28. A polymer, lubricant, paint, fibre, leather, paper, timber, foodstuff or water preserved against bacterial attack by being treated with a compound according to claim 1.
- 5 29. A penicillanic acid 1,1-dioxide as defined in claim 1 for use in combating bacterial infections. 5